SE0400683D0 - Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis - Google Patents

Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis

Info

Publication number
SE0400683D0
SE0400683D0 SE0400683A SE0400683A SE0400683D0 SE 0400683 D0 SE0400683 D0 SE 0400683D0 SE 0400683 A SE0400683 A SE 0400683A SE 0400683 A SE0400683 A SE 0400683A SE 0400683 D0 SE0400683 D0 SE 0400683D0
Authority
SE
Sweden
Prior art keywords
atherosclerosis
treatment
diagnosis
extracellular matrix
matrix proteins
Prior art date
Application number
SE0400683A
Other languages
English (en)
Inventor
Jan Nilsson
Original Assignee
Forskarpatent I Syd Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forskarpatent I Syd Ab filed Critical Forskarpatent I Syd Ab
Priority to SE0400683A priority Critical patent/SE0400683D0/sv
Publication of SE0400683D0 publication Critical patent/SE0400683D0/sv
Priority to PCT/SE2005/000394 priority patent/WO2005090974A1/en
Priority to EP05722239A priority patent/EP1756569A1/en
Priority to US11/523,366 priority patent/US20070104725A1/en
Priority to US12/814,137 priority patent/US20100279325A1/en
Priority to US13/569,051 priority patent/US8435532B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SE0400683A 2004-03-19 2004-03-19 Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis SE0400683D0 (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE0400683A SE0400683D0 (sv) 2004-03-19 2004-03-19 Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
PCT/SE2005/000394 WO2005090974A1 (en) 2004-03-19 2005-03-17 Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis
EP05722239A EP1756569A1 (en) 2004-03-19 2005-03-17 Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis
US11/523,366 US20070104725A1 (en) 2004-03-19 2006-09-19 Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis
US12/814,137 US20100279325A1 (en) 2004-03-19 2010-06-11 Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis
US13/569,051 US8435532B2 (en) 2004-03-19 2012-08-07 Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0400683A SE0400683D0 (sv) 2004-03-19 2004-03-19 Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis

Publications (1)

Publication Number Publication Date
SE0400683D0 true SE0400683D0 (sv) 2004-03-19

Family

ID=32067440

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0400683A SE0400683D0 (sv) 2004-03-19 2004-03-19 Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis

Country Status (4)

Country Link
US (3) US20070104725A1 (sv)
EP (1) EP1756569A1 (sv)
SE (1) SE0400683D0 (sv)
WO (1) WO2005090974A1 (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059975A2 (en) * 2008-11-21 2010-05-27 Wisconsin Alumni Research Foundation Method for modulating atherosclerosis
US8852873B2 (en) 2012-04-13 2014-10-07 Diabetomics, Llc Maternal biomarkers for gestational diabetes
CN103645330A (zh) * 2013-12-24 2014-03-19 上海北加生化试剂有限公司 检测尿液中纤维连接蛋白浓度的试剂盒及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723649B2 (en) * 1995-12-26 2000-08-31 Alteon Inc. Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid

Also Published As

Publication number Publication date
EP1756569A1 (en) 2007-02-28
US20120301491A1 (en) 2012-11-29
US8435532B2 (en) 2013-05-07
WO2005090974A1 (en) 2005-09-29
US20070104725A1 (en) 2007-05-10
US20100279325A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
NL301089I2 (nl) imlifidase
NO2017027I1 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
BRPI0520677A2 (pt) identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina
GB2438802A (en) Structure of the hepatitis C virus NS5A protein
WO2006086799A3 (en) Prion-specific peptide reagents
DK3085783T3 (da) Bispecifikt antistof som substitution for funktionelle proteiner
EA200702193A1 (ru) Гликозилирование белков
WO2005016127A3 (en) Prion-specific peptide reagents
EP2409988A3 (en) Peptide fragments for inducing synthesis of extracellular matrix proteins
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
SG170749A1 (en) Anti-ilt7 antibody
BR112012010252A2 (pt) variantes de glicosilação de anticorpo
ATE408624T1 (de) Verfahren zur reinigung von fsh
BRPI0608342A2 (pt) antìgenos recombinantes quiméricos de toxoplasma gondii
WO2006131599A3 (en) Method of profiling a cell population
WO2008008482A3 (en) Altered br3-binding polypeptides
NO20075702L (no) Polymersjikt med lav fuktighet i ikke-autoklav fremgangsmate
WO2007018463A3 (en) Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
ATE449345T1 (de) Monitorierung von huntington's disease
MX2013013931A (es) Medios y metodos para diagnosticar y tratar esclerosis multiple.
EA200870058A1 (ru) Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран
WO2008024919A8 (en) Interferon antagonists, antibodies thereto, and associated methods of use
SE0400683D0 (sv) Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
GB0620255D0 (en) Antibody and uses thereof